Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.
暂无分享,去创建一个
[1] Farzad Mostashari,et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey , 2001, The Lancet.
[2] C. Keenan,et al. Revascularization in coronary artery disease. A review of randomized trial data. , 1998, The Western journal of medicine.
[3] J. Ioannidis,et al. Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis. , 1999, Controlled clinical trials.
[4] J. Kahan,et al. Dissemination of effectiveness and outcomes research. , 1995, Health policy.
[5] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[6] A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. , 1982, JAMA.
[7] D. Sackett,et al. Evidence based medicine: what it is and what it isn't , 1996, BMJ.
[8] Jacob Cohen. Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.
[9] J W Jukema,et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.
[10] C. Moore,et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.
[11] E. M. Hartwell. Boston , 1906 .
[12] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[13] G. Lowe,et al. ABC of Atrial Fibrillation: ANTITHROMBOTIC TREATMENT FOR ATRIAL FIBRILLATION , 1996, BMJ.
[14] L. Walter,et al. Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure. , 2004, JAMA.
[15] Anna C. Balazs,et al. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. , 1980, The New England journal of medicine.
[16] Marc Lipsitch,et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States , 2003, Nature Medicine.
[17] A. Roses,et al. Pharmacogenetics and future drug development and delivery , 2000, The Lancet.
[18] C. Gross,et al. Reporting the Recruitment Process in Clinical Trials: Who Are These Patients and How Did They Get There? , 2002, Annals of Internal Medicine.
[19] A. Hoes,et al. Penicillin for acute sore throat in children: randomised, double blind trial , 2003, BMJ : British Medical Journal.
[20] R W Makuch,et al. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. , 1996, Journal of clinical epidemiology.
[21] T. Sørensen. Which patients may be harmed by good treatments? , 1996, The Lancet.
[22] R. D'Agostino. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.
[23] T. Fahey. Applying the results of clinical trials to patients to general practice: perceived problems, strengths, assumptions, and challenges for the future. , 1998, The British journal of general practice : the journal of the Royal College of General Practitioners.
[24] A. Sinha,et al. Gene expression profile analysis by DNA microarrays: promise and pitfalls. , 2001, JAMA.
[25] Daniel R. O’Leary,et al. The outbreak of West Nile virus infection in the New York City area in 1999. , 2001, The New England journal of medicine.
[26] Sankey V. Williams,et al. Hospital and Patient Characteristics Associated With Death After Surgery: A Study of Adverse Occurrence and Failure to Rescue , 1992, Medical care.
[27] J Lomas,et al. Words without action? The production, dissemination, and impact of consensus recommendations. , 1991, Annual review of public health.
[28] W. Rosser,et al. Application of evidence from randomised controlled trials to general practice , 1999, The Lancet.
[29] N. Longford. Selection bias and treatment heterogeneity in clinical trials. , 1999, Statistics in medicine.
[30] Nigel T James. Scientific method and raw data should be considered , 1996, BMJ.
[31] P. Rothwell,et al. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. , 1999, Lancet.
[32] S Senn,et al. On wisdom after the event. , 1997, Journal of clinical epidemiology.
[33] Lynn Ordway,et al. Antecedents of adherence to medical recommendations: Results from the medical outcomes study , 1992, Journal of Behavioral Medicine.
[34] S. Senn. Individual response to treatment: is it a valid assumption? , 2004, BMJ : British Medical Journal.
[35] R. Weinshilboum. Inheritance and drug response. , 2003, The New England journal of medicine.
[36] D. Rubin,et al. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .
[37] K L Baird,et al. The new NIH and FDA medical research policies: targeting gender, promoting justice. , 1999, Journal of health politics, policy and law.
[38] A. Laupacis,et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .
[39] Ted J. Kaptchuk,et al. The Placebo Effect in Alternative Medicine: Can the Performance of a Healing Ritual Have Clinical Significance? , 2002, Annals of Internal Medicine.
[40] D. Sackett. Evidence-based medicine: how to practice and teach EBM: 2nd ed , 2000 .
[41] J. Lewis,et al. The case for cross-over trials in phase III. , 1995, Statistics in medicine.
[42] J M Lachin,et al. The use of response-adaptive designs in clinical trials. , 1993, Controlled clinical trials.
[43] An illustrative statistical analysis of cutoff-based randomized clinical trials , 1992 .
[44] M. Enkin,et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. , 1989, The New England journal of medicine.
[45] B. Lerer,et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia , 2001, Molecular Psychiatry.
[46] P. Little,et al. Clinical and psychosocial predictors of illness duration from randomised controlled trial of prescribing strategies for sore throat , 1999, BMJ.
[47] A. Saykin,et al. The relationship of APOE genotype to neuropsychological performance in long‐term cancer survivors treated with standard dose chemotherapy , 2003, Psycho-oncology.
[48] S S Ellenberg,et al. Randomized consent designs for clinical trials: an update. , 1992, Statistics in Medicine.
[49] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[50] T. Shakespeare,et al. Observational Studies , 2003 .
[51] J. Wittes,et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.
[52] S. Sindrup,et al. The pharmacogenetics of codeine hypoalgesia. , 1995, Pharmacogenetics.
[53] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[54] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[55] L A Moyé,et al. Evaluation of ethnic minorities and gender effects in clinical trials: opportunities lost and rediscovered. , 2001, Journal of the National Medical Association.
[56] G H Guyatt,et al. N of 1 randomized trials for investigating new drugs. , 1990, Controlled clinical trials.
[57] G. Taylor,et al. Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[58] P. Lachenbruch. Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .
[59] M. Mosteller,et al. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance. , 2002, British journal of clinical pharmacology.
[60] J. A. N. Eedleman,et al. Nurse-Staffing Levels and the Quality of Care in Hospitals , 2002 .
[61] T. Vulliamy,et al. Glucose-6-phosphate dehydrogenase deficiency. , 2000, Bailliere's best practice & research. Clinical haematology.
[62] C D Naylor,et al. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. , 2000, American heart journal.
[63] E. Oren,et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.
[64] Aniruddha M. Deshpande,et al. Standardized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guideline Standardization , 2003, Annals of Internal Medicine.
[65] G H Guyatt,et al. Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. , 1998, JAMA.
[66] S. Satya‐Murti. Evidence-based Medicine: How to Practice and Teach EBM , 1997 .
[67] S. Tanenbaum,et al. What physicians know. , 1993, The New England journal of medicine.
[68] A. Berg. Chemoprevention of breast cancer: recommendations and rationale. , 2003, The American journal of nursing.
[69] Siep Thomas,et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study , 1998, BMJ.
[70] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[71] G. Lip. ABC of atrial fibrillation , 1996 .
[72] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.
[73] H. Petersen,et al. Combined single subject trials. , 1991, Scandinavian journal of primary health care.
[74] P. Allmark,et al. Should research samples reflect the diversity of the population? , 2004, Journal of Medical Ethics.
[75] G H Guyatt,et al. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. , 2000, JAMA.
[76] S. Rössner,et al. Coronary Drug Project Research Group. , 1978, Atherosclerosis.
[77] A. Hall,et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. , 2002, Molecular pharmacology.
[78] N T Longford,et al. Statistics versus statistical science in the regulatory process. , 1999, Statistics in medicine.
[79] A. Feinstein,et al. Problems in the "evidence" of "evidence-based medicine". , 1997, The American journal of medicine.
[80] Les M Irwig,et al. An evidence based approach to individualising treatment , 1995, BMJ.
[81] M Schumacher,et al. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. , 1995, Statistics in medicine.